Coherus Biosciences Inc. (CHRS) Rose To Over A 2-Month High On Study Results

Coherus Biosciences Inc. (CHRS) announced Monday morning that its follow-on pharmacokinetic and pharmacodynamic clinical study of CHS-1701 met all of its co-primary endpoints.

from RTT - Before the Bell http://ift.tt/29Bdu08
via IFTTT